Euglena polysaccharide uric acid reducing composition and preparation method thereof

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to an euglena polysaccharide uric acid reducing composition and a preparation method thereof. Comprising 7 to 8 parts of goose carnosine, 4 to 6 parts of celery seed powder, 0.3 to 0.5 part of sour cherry extract, 0.15 to 0.2 part of ginsenoside, 15 to 25 parts of chlorella active peptide, 10 to 14 parts of phellodendron chinense concentrated powder, 9 to 11 parts of coptis chinensis concentrated powder and 0.005 to 0.01 part of euglena polysaccharide. The preparation method comprises the following steps: arranging a formula amount of euglena polysaccharide on the outer surface of the core, and air-drying at normal temperature until the water content is less than or equal to The composition is conventionally used in a chewing mode, can play a role in reducing uric acid in blood after being used for a long time, and can be used as a health-care product for relieving gout and hyperuricemia symptoms; in emergency, the composition can be pinched to be cracked, put into water to be imbibed and then externally applied as an emergency pain-relieving plaster to be applied to an affected part for relieving pain.

Description

Technical Field

[0001] The present invention relates to the field of health care technologies, and in particular to a Euglena polysaccharide composition for reducing uric acid and a preparation method thereof. Background Art

[0002] Euglena can be used to reduce blood uric acid. For example, a Chinese patent discloses a Euglena extract for removing body oil and a preparation method thereof, with the authorization announcement number CN108721339B. It is recorded therein: The present invention cultures Euglena with high nutritional components, and then obtains a Euglena extract composed of various active substances including Euglena polysaccharide through water extraction and alcohol precipitation. Compared with the prior art, the Euglena extract for removing body oil prepared by the present invention has various effects such as inhibiting purine absorption, treating diabetes, removing body oil, slimming, and reducing blood uric acid.

[0003] However, it should be noted that: The Euglena extract can reduce the blood uric acid concentration by inhibiting purine absorption, but it cannot inhibit the pain caused by high uric acid.

[0004] In addition, existing Euglena polysaccharide products are generally taken in the form of compressed tablets (such as the Euglena compressed tablet named "Huazhong Euglena Suqingsu"), and the sugar content (maltose, granulated sugar, glucose syrup or sucrose) exceeds 40wt%. As is well known, fructose consumes a large amount of adenosine triphosphate (ATP) during the liver metabolism process, resulting in an increase in purine decomposition and ultimately generating more uric acid; in addition, the metabolites of fructose also inhibit uric acid excretion; a high-sugar diet may cause insulin resistance, and an increase in insulin level will reduce the excretion of uric acid by the kidneys, resulting in the retention of uric acid in the body.

[0005] There is an urgent need for a Euglena polysaccharide composition for reducing uric acid, which can not only reduce blood uric acid but also relieve the pain caused by high uric acid, and does not add sugars such as maltose, granulated sugar, glucose syrup or sucrose as a molding agent to avoid excessive sugar intake. Summary of the Invention

[0006] Aiming at the deficiencies of the prior art, one of the purposes of the present invention is to provide a Euglena polysaccharide composition for reducing uric acid, and the second purpose of the present invention is to provide a preparation method of the Euglena polysaccharide composition for reducing uric acid.

[0007] One of the purposes of the present invention is achieved through the following technical solutions: A Euglena polysaccharide composition for reducing uric acid, comprising the following components in parts by weight: 7-8 parts of anserine, 4-6 parts of celery seed powder, 0.3-0.5 part of tart cherry extract, 0.15-0.2 part of ginsenoside, 15-25 parts of chlorella active peptide, 10-14 parts of Phellodendri chinensis concentrated powder, 9-11 parts of Coptidis rhizoma concentrated powder, and 0.005-0.01 part of Euglena polysaccharide.

[0008] In a preferred embodiment, 7.5 parts of anserine, 5 parts of celery seed powder, 0.4 part of tart cherry extract, 0.17 part of ginsenoside, 20 parts of chlorella active peptide, 12 parts of Phellodendri Chinensis Concentrate Powder, 10 parts of Coptidis Rhizoma Concentrate Powder, and 0.005 part of euglena polysaccharide.

[0009] The second object of the present invention is achieved by the following technical solutions: A preparation method of an euglena polysaccharide composition for reducing uric acid, comprising the following steps: Step 1: Weigh anserine, celery seed powder, tart cherry extract, ginsenoside, chlorella active peptide, Phellodendri Chinensis Concentrate Powder, and Coptidis Rhizoma Concentrate Powder according to the formula amount; Step 2: Add Phellodendri Chinensis Concentrate Powder to 20 - 25 times its weight of deionized water, and stir evenly at 90 - 100 °C to obtain a raw pulp; Step 3: Keep warm and add celery seed powder, tart cherry extract, and Coptidis Rhizoma Concentrate Powder to the raw pulp, and stir evenly to obtain a secondary pulp; Step 4: Cool the secondary pulp to 30 - 35 °C, then add anserine, ginsenoside, and chlorella active peptide, stir vigorously, and then dry at room temperature until the water content is 40% to obtain a thick pulp; Step 5: Feed the thick pulp into an extruder, and obtain a medicine core through extrusion, granulation, and pill rolling; Step 6: Set the formula amount of euglena polysaccharide on the outer surface of the medicine core, and then air-dry at room temperature until the water content ≤ 9% to obtain the composition.

[0010] In a preferred embodiment, the stirring method in Step 2 and Step 3 is to stir at a speed of 20 - 50 r / min for 20 - 30 min. Stirring at a lower rate for a long time can preferentially disperse insoluble substances (celery seed powder, tart cherry extract, and Coptidis Rhizoma Concentrate Powder) on the premise of generating fewer bubbles.

[0011] In a preferred embodiment, the method of vigorous stirring in Step 4 is to stir at a speed of 1200 - 2000 r / min for 3 - 5 min. After the first two low-speed stirrings, the slurry has become relatively thick, and it is difficult to disperse the materials without vigorous stirring at this time.

[0012] In a preferred embodiment, the method of setting euglena polysaccharide on the outer surface of the medicine core is as follows: Then, put the nanoscale powder into the lecithin alcohol solution according to a mass ratio of 5:95 to obtain a mixture. The lecithin content in the lecithin alcohol solution is 2 wt%. Use ultrasonic waves to disperse the mixture into a stable suspension. At the same time, air-dry the medicine core until the water content is 9%; put the medicine core into a coating machine, and evenly coat the stable suspension on the surface of the medicine core through the coating machine and dry it. After the weight gain reaches the formula amount of euglena polysaccharide, the coating is completed.

[0013] Setting the polysaccharide from Euglena gracilis in this way is obviously more costly and technically more complex than ordinary mixing. However, it is easy to understand that due to the film-forming property of the stable suspension after drying, the polysaccharide from Euglena gracilis can wrap the medicine core more completely, and then utilize the property that the polysaccharide from Euglena gracilis is insoluble in water to protect the medicine core from sticking to each other easily during production, transportation and use.

[0014] In a preferred embodiment, the ultrasonic frequency is 40 kHz and the dispersion time is 5 min.

[0015] The beneficial effects of the present invention are as follows: The conventional usage method of this composition is chewing (the same as the taking method of compressed tablets, but this composition does not use sugars as a molding agent to avoid excessive sugar intake). Long-term use can play a role in reducing uric acid in the blood and can be used as a health product for relieving gout and high uric acid symptoms. In case of emergency, this composition can also be cracked and put into water to absorb water and then used externally as an emergency pain-relieving plaster and applied to the affected area to relieve pain. Detailed implementation manners

[0016] The following is further described in conjunction with the detailed implementation manners: Example 1 Weigh 7 parts of carnosine, 4 parts of celery seed powder, 0.3 part of tart cherry extract, 0.15 part of ginsenoside, 15 parts of chlorella active peptide, 10 parts of Phellodendri chinensis concentrated powder and 9 parts of Coptidis chinensis concentrated powder by weight.

[0017] Add the Phellodendri chinensis concentrated powder to 20 times its weight of deionized water, and stir at a speed of 20 r / min for 20 min at 90 °C to obtain the original pulp.

[0018] Keep warm and add the celery seed powder, tart cherry extract and Coptidis chinensis concentrated powder to the original pulp, and stir at a speed of 20 r / min for 20 min to obtain the secondary pulp.

[0019] Cool the secondary pulp to 30 °C, then add carnosine, ginsenoside and chlorella active peptide, stir at a speed of 1200 r / min for 3 min, and then dry at room temperature until the water content is 40% to obtain the thick pulp.

[0020] Send the thick pulp into an extruder, and obtain the medicine core (2 g ± 5%) through extrusion, granulation and pill rolling.

[0021] Grind the polysaccharide from Euglena gracilis into a nano-scale powder with a particle size of ≤ 500 nm.

[0022] Subsequently, the nanoscale powder was put into the lecithin alcohol solution according to a mass ratio of 5:95 to obtain a mixture. The lecithin content in the lecithin alcohol solution was 2 wt%. The mixture was dispersed into a stable suspension using ultrasonic waves (40 kHz, 5 min, the same hereinafter). At the same time, the core of the medicine was air-dried until the water content reached 9%. 5 kg of the core of the medicine was put into a coating machine (model: LAB-COAT LDCS-20, the same hereinafter). The stable suspension was evenly coated on the surface of the core of the medicine through the coating machine and dried. The weighing showed 5.05 kg, with a weight gain of 0.05 kg reaching the formula amount of euglena polysaccharide (0.05÷5.05≈0.0099, meeting the standard of 0.005 - 0.01 parts of euglena polysaccharide), and the coating was completed.

[0023] Air-dry at room temperature until the water content reaches 9% (since the present invention does not have high requirements for the film-forming flatness and does not require shaping treatment. Additionally, if the water content of the composition after coating the stable suspension is ≤9%, this step of air-drying at room temperature is omitted. The same hereinafter), to obtain the composition.

[0024] Example 2 Weigh 8 parts of anserine, 6 parts of celery seed powder, 0.5 part of tart cherry extract, 0.2 part of ginsenoside, 25 parts of chlorella active peptide, 14 parts of Phellodendron amurense concentrated powder, and 11 parts of Coptis chinensis concentrated powder by weight.

[0025] Add the Phellodendron amurense concentrated powder to 25 times its weight of deionized water, and stir at 50 r / min for 30 min at 100 °C to obtain the original pulp; Keep warm and add the celery seed powder, tart cherry extract, and Coptis chinensis concentrated powder to the original pulp, and stir at 50 r / min for 30 min to obtain the secondary pulp; Cool the secondary pulp to 35 °C, then add anserine, ginsenoside, and chlorella active peptide, stir at 2000 r / min for 5 min, and then dry at room temperature until the water content reaches 40% to obtain the thick pulp; Feed the thick pulp into an extruder, and obtain the core of the medicine (2 g ± 5%) through extrusion, granulation, and pill rolling; Grind the euglena polysaccharide into nanoscale powder with a size of ≤500 nm.

[0026] Subsequently, the nanoscale powder was put into the lecithin alcohol solution according to a mass ratio of 5:95 to obtain a mixture. The lecithin content in the lecithin alcohol solution was 2 wt%. The mixture was dispersed into a stable suspension using ultrasonic waves. At the same time, the core of the medicine was air-dried until the water content reached 9%. 6 kg of the core of the medicine was put into a coating machine. The stable suspension was evenly coated on the surface of the core of the medicine through the coating machine and dried. The weighing showed 6.05 kg, with a weight gain of 0.05 kg reaching the formula amount of euglena polysaccharide (0.05÷6.05≈0.0083, meeting the standard of 0.005 - 0.01 parts of euglena polysaccharide), and the coating was completed.

[0027] Air-dry at room temperature until the water content reaches 9% to obtain the composition.

[0028] Example 3 Weigh 7.5 parts of carnosine, 5 parts of celery seed powder, 0.4 part of tart cherry extract, 0.17 part of ginsenoside, 20 parts of chlorella active peptide, 12 parts of Phellodendri Chinensis concentrated powder, and 10 parts of Coptidis Rhizoma concentrated powder by weight.

[0029] Add the Phellodendri Chinensis concentrated powder to 22 times its weight of deionized water, stir at 35 r / min for 25 min at 95 °C to obtain the primary pulp; Keep warm and add celery seed powder, tart cherry extract, and Coptidis Rhizoma concentrated powder to the primary pulp, stir at 35 r / min for 25 min to obtain the secondary pulp; Cool the secondary pulp to 33 °C, then add carnosine, ginsenoside, and chlorella active peptide, stir at 1700 r / min for 4 min, and then dry at room temperature until the water content reaches 40% to obtain the thick pulp; Feed the thick pulp into an extruder, and obtain the medicine core through extrusion, granulation, and pill rolling; Grind the euglena polysaccharide into nanoscale powder with a particle size of ≤500 nm.

[0030] Then, add the nanoscale powder to the lecithin alcohol solution at a mass ratio of 5:95. The lecithin content in the lecithin alcohol solution is 2 wt%. Use ultrasonic waves to disperse the mixture into a stable suspension. At the same time, air-dry the medicine core until the water content reaches 9%; Put 10 kg of the medicine core into a coating machine, and evenly coat the stable suspension on the surface of the medicine core through the coating machine and dry it. The weighing shows 10.05 kg, with a weight gain of 0.05 kg, reaching the euglena polysaccharide formulation amount (0.05÷10.05≈0.0050, meeting the standard of 0.005 - 0.01 parts of euglena polysaccharide), and the coating is completed.

[0031] Comparative Example 1 Weigh 7.5 parts of carnosine, 5 parts of celery seed powder, 0.4 part of tart cherry extract, 0.17 part of ginsenoside, 20 parts of chlorella active peptide, 12 parts of Phellodendri Chinensis concentrated powder, 10 parts of Coptidis Rhizoma concentrated powder, and 0.0067 part of euglena polysaccharide by weight.

[0032] Add the Phellodendri Chinensis concentrated powder to 22 times its weight of deionized water, stir at 35 r / min for 25 min at 95 °C to obtain the primary pulp; Keep warm and add celery seed powder, tart cherry extract, and Coptidis Rhizoma concentrated powder to the primary pulp, stir at 35 r / min for 25 min to obtain the secondary pulp; Cool the secondary pulp to 33 °C, then add carnosine, ginsenoside, chlorella active peptide, and euglena polysaccharide, stir at 1700 r / min for 4 min, and then dry at room temperature until the water content reaches 40% to obtain the thick pulp; Feed the thick paste into an extruder, and obtain the medicine core through extrusion, granulation and pill rolling. Air-dry at room temperature until the water content reaches 9% to obtain the composition.

[0033] Comparative Example 2 Replace carnosine and chlorella active peptide with an equal amount of quercetin and wheat polypeptide respectively, and the remaining steps are the same as those in Example 3.

[0034] Experiment 1 - Anti-adhesion experiment To verify that the composition obtained by the present invention has an excellent anti-adhesion effect, take 50 pills each of Examples 1-3 and Comparative Examples 1-2 and seal them in plastic bottles respectively. In an environment with a temperature of 25°C and a relative humidity of 75%, open the bottle cap every day to take 1 pill and time for 1 minute, and then close the bottle cap. After 25 days (that is, after taking away 25 pills), let the remaining compositions stand in the middle position of A8 paper for 5 minutes. Lift the compositions with tweezers respectively, and at the same time observe whether the paper can be lifted by the adhesion. Count the number that can be lifted in each group.

[0035] The experimental results are shown in Table 1.

[0036] Table 1 Statistics of the number of lifted ones As can be seen from Table 1, in Comparative Example 1, the Euglena polysaccharide was directly mixed into the composition instead of being set on the surface, making it difficult to achieve the moisture-proof and anti-adhesion effects on the composition.

[0037] Experiment 2 - Plaster adhesion experiment To verify that the composition obtained by the present invention can be used externally as an emergency pain-relieving plaster coating after being crushed and swollen in water (that is, at least the whole composition can adhere to the skin and will not fall off in a large area), take 1 pill each of Examples 1-3 and Comparative Examples 1-2, crack them and place them on the cap of a mineral water bottle filled with water (2 mL of water), let them stand and swell, then stir and coat the outer side of a fresh pigskin with a length and width of 5 cm and 5 cm respectively. The coating area is about 9 cm 2 , fix the inner side of the pigskin to the left side of a PVC plastic plate (with a thickness of 6 mm) vertically set on the table with 502 glue. The distance between the bottom end of the pigskin and the table is 10 cm. Use a fascia gun with a rated power of 24 W to vibrate the right side of the plastic plate at a vibration frequency of 1000 times / min for 10 s at a position directly behind the pigskin. Before that, lay a plastic film under the plastic plate to collect the fallen debris, and then weigh it. Repeat 3 times, and count the average weight of the debris in each group. The results are shown in Table 2.

[0038] Table 2 Statistics of the average weight of debris As can be seen from Table 2, the composition obtained in the present invention can adhere firmly to the skin even without using any adhesive after imbibition, and is suitable for use as an emergency pain-relieving plaster. It can also be seen from Comparative Example 2 that after replacing carnosine and chlorella active peptide with quercetin and wheat polypeptide with similar effects respectively, the adhesiveness is significantly reduced. In addition, in Comparative Example 1, because the polysaccharide of Euglena gracilis is evenly distributed in the composition, although the polysaccharide of Euglena gracilis itself is insoluble in water, since it is in powder particles and dispersed everywhere in the composition and does not form hard lumps, it is not easy to fall off during vibration. In other examples or comparative examples, because the polysaccharide of Euglena gracilis is concentrated on the surface, the damaged polysaccharide film of Euglena gracilis is easy to form a small amount of small hard lumps after the composition is crushed, and it is easy to agglomerate during stirring, so some hard lumps are easy to carry a certain amount of other components and fall off during vibration. In Comparative Example 2, due to the difference in the core ingredients of the medicine, the adhesiveness is poor after imbibition, and not only the hard lumps fall off during vibration, but also some core ingredients of the medicine fall off due to vibration.

[0039] Although setting the polysaccharide of Euglena gracilis on the surface of the medicine core will cause the adhesiveness of the composition to decrease when used as an emergency pain-relieving plaster, because it brings effects such as moisture-proof and anti-adhesion, and the adhesiveness is still within an acceptable range (there is no overall shedding during vibration), so this application can tolerate this defect.

[0040] Experiment 3 - Pain Relief Experiment To verify that the composition obtained in the present invention has a pain-relieving effect when crushed and put into water for imbibition and then used externally as an emergency pain-relieving plaster, an experiment was carried out: 27 KM mice (20g ± 10%) provided by Changsha Tianqin Biotechnology Co., Ltd. were randomly and evenly divided into 3 groups. The first group was the control group, the second group was the pethidine group, and the third group was the experimental group. The hind feet of the control group were coated with 1g of gel (0.5g on each side, the same below), the pethidine group was injected with medicine at 25mg / kg and the hind feet were coated with 1g of gel, and the hind feet of the experimental group were coated with 1g of the emergency pain-relieving plaster obtained in Example 3 of Experiment 2. 15 minutes after medication, 0.03ml of 2.5% formaldehyde was injected into the right hind foot. Medication was given once again, and then the average number of times the mice licked the right hind foot was observed and counted. The results are shown in Table 3.

[0041] Table 3 Statistics of the number of times of licking the right hind foot As can be seen from Table 3, Example 3 can effectively relieve pain when used as an emergency pain-relieving plaster. That is to say, the composition obtained in the present invention can not only be used as a daily health care product to control blood uric acid, but also be temporarily used as an emergency pain-relieving plaster. Carrying this composition as a health care product for controlling uric acid and taking it daily can control uric acid. When a gout attack occurs outdoors, in a vehicle, in the wild, etc. and it is impossible to seek medical treatment, this composition can be used to temporarily relieve pain.

[0042] Source description of the materials used in each example and comparative example The remaining raw materials not specifically described are purchased through conventional channels.

[0043] The above-described embodiments and the descriptions in the specification only illustrate the principles and the best embodiments of the present invention. Without departing from the spirit and scope of the present invention, the present invention will have various changes and improvements, and these changes and improvements all fall within the scope of the present invention claimed.

Claims

1. A polysaccharide of Euglena gracilis composition for reducing uric acid, characterized in that, It comprises the following components in parts by weight: anserine 7 - 8 parts, celery seed powder 4 - 6 parts, tart cherry extract 0.3 - 0.5 parts, ginsenoside 0.15 - 0.2 parts, chlorella active peptide 15 - 25 parts, Phellodendri Chinensis Schneid concentrated powder 10 - 14 parts, Coptidis Rhizoma concentrated powder 9 - 11 parts, and euglena polysaccharide 0.005 - 0.01 part.

2. The composition according to claim 1, wherein It comprises the following components in parts by weight: anserine 7.5 parts, celery seed powder 5 parts, tart cherry extract 0.4 part, ginsenoside 0.17 part, chlorella active peptide 20 parts, Phellodendri Chinensis Schneid concentrated powder 12 parts, Coptidis Rhizoma concentrated powder 10 parts, and euglena polysaccharide 0.005 part.

3. A preparation method of the euglena polysaccharide uric acid-lowering composition according to claim 1, characterized in that, It comprises the following steps: Step 1: Weigh anserine, celery seed powder, tart cherry extract, ginsenoside, chlorella active peptide, Phellodendri Chinensis Schneid concentrated powder, and Coptidis Rhizoma concentrated powder according to the formula amount. Step 2: Add Phellodendri Chinensis Schneid concentrated powder into deionized water with a weight 20 - 25 times that of the powder, and stir evenly at 90 - 100 °C to obtain the original pulp. Step 3: Keep warm and add celery seed powder, tart cherry extract, and Coptidis Rhizoma concentrated powder into the original pulp, and stir evenly to obtain the second pulp. Step 4: Cool the second pulp to 30 - 35 °C, then add anserine, ginsenoside, and chlorella active peptide, stir vigorously, and dry at room temperature until the water content is 40% to obtain the thick pulp. Step 5: Feed the thick pulp into an extruder, and obtain the medicine core through extrusion, granulation, and pill rolling. Step 6: Set the euglena polysaccharide with the formula amount on the surface of the medicine core, and air-dry at room temperature until the water content ≤ 9% to obtain the composition.

4. The preparation method according to claim 3, characterized in that, The stirring method in Step 2 and Step 3 is to stir at a speed of 20 - 50 r / min for 20 - 30 min.

5. The preparation method according to claim 3, characterized in that, The method of vigorous stirring in Step 4 is to stir at a speed of 1200 - 2000 r / min for 3 - 5 min.

6. The preparation method according to claim 3, characterized in that, The method of setting euglena polysaccharide on the surface of the medicine core is as follows: Then, put the nanoscale powder into the lecithin alcohol solution according to the mass ratio of 5:95 to obtain a mixture. The lecithin content in the lecithin alcohol solution is 2 wt%. Use ultrasonic waves to disperse the mixture into a stable suspension. At the same time, air-dry the medicine core until the water content is 9%. Put the medicine core into a coating machine, and evenly coat the stable suspension on the surface of the medicine core through the coating machine and dry it. After the weight gain reaches the formula amount of euglena polysaccharide, the coating is completed.

7. The preparation method according to claim 6, characterized in that, The ultrasonic frequency is 40 kHz, and the dispersion time is 5 min.

Images